Copyright
©2014 Baishideng Publishing Group Inc.
World J Clin Oncol. Dec 10, 2014; 5(5): 966-972
Published online Dec 10, 2014. doi: 10.5306/wjco.v5.i5.966
Published online Dec 10, 2014. doi: 10.5306/wjco.v5.i5.966
Table 4 Tax 323 and 324 Protocols
| Tax 323 study | Tax 324 Study | |
| Stages | III, IV | III, IV |
| Induction therapy regimens | TPF: docetaxel 75 mg/m2 day 1, cisplatin 75 mg/m2 day 1, fluorouracil infusion 750 mg/m2 per day continuous infusion day 1 to 5 | TPF: docetaxel 75 mg/m2 day 1, cisplatin 100 mg/m2 day 1, fluorouracil 1000 mg/m2 per day, continuous 24 h IV infusion for 4 d |
| PF: cisplatin 100 mg/m2 day 1, fluorouracil 1000 mg/m2 continuous infusion days 1 to 5 | PF: cisplatin 100 mg/m2 day 1, fluorouracil 1000 mg/m2 per 24 h continuous infusion for 5 d | |
| Concurrent therapy regimens | Start 4-7 wk after completing induction therapy: | Start 3-8 wk after completing induction therapy: |
| Radiation administered over 7 wk, either conventional (66 to 70 Gy), accelerated (70 Gy) or hyperfractionated (74 Gy) | Radiation 2 Gy per day, 5 d a week for a total of 70-74 Gy plus weekly carboplatin AUC 1.5 |
- Citation: Georges P, Rajagopalan K, Leon C, Singh P, Ahmad N, Nader K, Kubicek GJ. Chemotherapy advances in locally advanced head and neck cancer. World J Clin Oncol 2014; 5(5): 966-972
- URL: https://www.wjgnet.com/2218-4333/full/v5/i5/966.htm
- DOI: https://dx.doi.org/10.5306/wjco.v5.i5.966